Algorithm based on CMV kinetics DNA viral load for preemptive therapy initiation after hematopoietic cell transplantation
- 24 January 2011
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 83 (3) , 490-495
Abstract
Preemptive therapy in hematopoietic cell transplantation is initiated by a diagnostic technique at first detection of cytomegalovirus (CMV). The aim of this study was to use the viral dynamics of CMV DNA viral to start preemptive therapy, and to prospectively compare the CMV viral load kinetics to pp65 antigenemia. Two hundred sixty‐three blood samples were collected prospectively from 93 patients. All clinical decisions regarding use of preemptive therapy were based on CMV antigenemia. Based on the positivity of the antigen assay and clinical CMV outcome in allotransplant patients, an optimal threshold of 3.05 log 10 (1,130 copies/ml) was found to discriminate patients who required preemptive therapy and those who did not (sensitivity, 71%; specificity, 65%). A DNAemia level increase of 2.24 log 10 (174 copies/ml) per day was the optimal threshold to discriminate between patients who required preemptive therapy and those who did not (sensitivity, 93%; specificity, 43%). Sensitivity of PCR assay was 92.4% compared with 39% for the antigen assay (P < 0.001). A standardized real‐time PCR assay is more appropriate than the antigen assay for detecting CMV. It allowed earlier diagnosis of active CMV infection and monitoring of the response to anti‐CMV treatment. J. Med. Virol. 83:490–495, 2011.Keywords
This publication has 34 references indexed in Scilit:
- How we treat cytomegalovirus in hematopoietic cell transplant recipientsBlood, 2009
- An Assessment of Herpesvirus Co-infections in Patients with CMV Disease: Correlation with Clinical and Virologic OutcomesAmerican Journal of Transplantation, 2009
- Quantification of DNA in Plasma by an Automated Real-Time PCR Assay (Cytomegalovirus PCR Kit) for Surveillance of Active Cytomegalovirus Infection and Guidance of Preemptive Therapy for Allogeneic Hematopoietic Stem Cell Transplant RecipientsJournal of Clinical Microbiology, 2008
- Cytomegalovirus DNA Measurement in Blood and Plasma Using Roche LightCycler CMV Quantification ReagentsDiagnostic Molecular Pathology, 2008
- Evaluation of Real-Time PCR Laboratory-Developed Tests Using Analyte-Specific Reagents for Cytomegalovirus QuantificationJournal of Clinical Microbiology, 2007
- Analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay, the amplicor CMV test, and a semi‐quantitative polymerase chain reaction test after allogeneic marrow transplantationTransplant Infectious Disease, 2007
- Evaluation of the COBAS Amplicor HCMV Monitor for early detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantationBone Marrow Transplantation, 2006
- Comparison of quantitative competitive polymerase chain reaction–enzyme-linked immunosorbent assay with LightCycler-based polymerase chain reaction for measuring cytomegalovirus DNA in patients after hematopoietic stem cell transplantationDiagnostic Microbiology and Infectious Disease, 2006
- Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load ⩾10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patientsBone Marrow Transplantation, 2005
- Molecular Methods for Cytomegalovirus Surveillance in Bone Marrow Transplant RecipientsJournal of Clinical Microbiology, 2002